Chicago: New Technologies Help Drugs Cross Blood-Brain Barrier
Designing compounds to fight neurodegenerative disease comes with the additional challenge of making sure they actually reach the brain...
6366 RESULTS
Sort By:
Designing compounds to fight neurodegenerative disease comes with the additional challenge of making sure they actually reach the brain...
In the past two years, a closer look at epilepsy and Alzheimer disease has revealed some fundamental similarities...
The SfN annual meeting featured a rare convergence of epilepsy and Alzheimer disease researchers at a symposium focused on shared features of these two disorders...
Researchers have identified an unusual gene that keeps a lid on both amyloid production and tau phosphorylation in mouse brain...
A new mouse model of combined Aβ and tau pathology reveals that the pair deliver a one-two punch to mitochondria...
It’s refreshing to hear about studies showing clear convergence between biology, drug action, and behavior, all in the space of a few seconds, no less...
Relationships forged amidst the glitz and glamour of Las Vegas have a reputation for ending badly; the one between the University of Nevada, Reno (UNR), and the Lou Ruvo Brain Institute (LRBI) was apparently no exception...
At a satellite symposium, “Nicotinic Acetylcholine Receptors (nAChRs) as Therapeutic Targets,” clinical discussion of cognitive treatments focused largely on nAChR agonists...
Days before the masses swarmed to the SfN annual meeting, a more intimate assembly of 287 exchanged the latest buzz on nicotinic acetylcholine receptors...
In Alzheimer disease research, focus has recently shifted away from large plaques and toward small oligomers of amyloid as a potential cause of disease...
The window of opportunity for regenerating nerves severed in spinal cord injuries may be more expansive than previously thought...
The long axons of neurons act as intracellular highways, with motor proteins shuttling their cargo up and down microtubule tracks...
St. Louis: Scientists, Families Target Preclinical Detection, Trials St. Louis: The Family View—What Do Study Volunteers Want From DIAN? St. Louis: Cognition Pre-dementia—Like eFAD, Like LOAD? St. Louis: Biomarkers Pre-dementia—Like eFAD, Like LOAD? St. L
DIAN was founded with the hope that its participating families could be offered a prevention trial and/or treatment trial before too long...
At the 7th Leonard Berg Symposium, brain imaging researchers of various stripes took stock of what brain imaging tells the field about the preclinical period of Alzheimer disease...